Harold E Bays
Overview
Explore the profile of Harold E Bays including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
147
Citations
4872
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bays H, Bloedon L, Brennan D, Lei L, Lincoff A, Nicholls S, et al.
J Am Heart Assoc
. 2025 Feb;
14(4):e037898.
PMID: 39921511
Background: Obesity and hypercholesterolemia independently increase cardiovascular disease risk. This analysis evaluated the efficacy and safety of bempedoic acid in people with obesity participating in the CLEAR (Cholesterol Lowering via...
2.
Ard J, Ryan D, ONeil P, Kushner R, Wyatt H, Bays H, et al.
Obesity (Silver Spring)
. 2025 Feb;
33(3):500-511.
PMID: 39904726
Objective: The objective of this study was to investigate the efficacy and safety of the Epitomee capsule versus placebo as an adjunct to high-intensity lifestyle intervention in participants with overweight...
3.
Bhatt D, Bays H, Miller M, Cain 3rd J, Wasilewska K, Andrawis N, et al.
Nat Med
. 2024 Mar;
30(6):1788-1789.
PMID: 38438737
No abstract available.
4.
Bays H, Hsia D, Nguyen L, Peterson C, Varghese S
Obes Pillars
. 2024 Feb;
9:100099.
PMID: 38304225
Background: A fixed-dose combination of phentermine and extended-release topiramate (PHEN/TPM - approved for weight management) has demonstrated in-clinic reduction of blood pressure (BP). Ambulatory BP monitoring (ABPM) may be a...
5.
Aronne L, Sattar N, Horn D, Bays H, Wharton S, Lin W, et al.
JAMA
. 2023 Dec;
331(1):38-48.
PMID: 38078870
Importance: The effect of continued treatment with tirzepatide on maintaining initial weight reduction is unknown. Objective: To assess the effect of tirzepatide, with diet and physical activity, on the maintenance...
6.
Bays H, Fitch A, Christensen S, Burridge K, Tondt J
Obes Pillars
. 2023 Nov;
2:100018.
PMID: 37990711
Background: This "Anti-Obesity Medications and Investigational Agents: An Obesity Medicine Association Clinical Practice Statement 2022" is intended to provide clinicians an overview of Food and Drug Administration (FDA) approved anti-obesity...
7.
Fitch A, Bays H
Obes Pillars
. 2023 Nov;
1:100004.
PMID: 37990702
Background: The Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) regarding definition, diagnosis, bias, standard operating procedures (SOPs) and telehealth is intended to provide clinicians an overview of obesity medicine...
8.
Burridge K, Christensen S, Golden A, Ingersoll A, Tondt J, Bays H
Obes Pillars
. 2023 Nov;
1:100007.
PMID: 37990700
Background: This Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) on History, Physical Exam, Body Composition and Energy Expenditure is intended to provide clinicians an overview of the clinical and...
9.
Bays H, Fitch A, Christensen S, Burridge K, Tondt J
Obes Pillars
. 2023 Nov;
4:100035.
PMID: 37990671
[This corrects the article DOI: 10.1016/j.obpill.2022.100018.].
10.
Bays H, Bloedon L, Lin G, Powell H, Louie M, Nicholls S, et al.
J Clin Lipidol
. 2023 Nov;
18(1):e59-e69.
PMID: 37951797
Background: Bempedoic acid is an oral adenosine triphosphate citrate lyase (ACL) inhibitor that lowers low-density lipoprotein cholesterol (LDL-C) blood levels. The Cholesterol Lowering via Bempedoic acid, an ACL-Inhibiting Regimen (CLEAR)...